Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LongeveronLGVN +1.40%45 Pretax Margin % is -1,189.95% as of Mar. 2026. GuruFocus rates LGVN with a GF Score™ of 45/100 and a GF Value™ of $0.38 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 942 Biotechnology companies, Longeveron ranks worse than 83.33% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Longeveron's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-4.74 Mil. Longeveron's Revenue for the
three
months ended in Mar. 2026 was $0.40 Mil. Therefore, Longeveron's pretax margin for the quarter that ended in Mar. 2026 was -1,189.95%.
The historical rank and industry rank for Longeveron's Pretax Margin % or its related term are showing as below:
LGVN'
s Pretax Margin % Range Over the Past 10 Years
Min: -3020.17 Med: -986.45 Max: -66.09
Current: -1844.49
LGVN's Pretax Margin % is ranked worse than 83.33% of 942
companies
in the Biotechnology industry
Industry Median: -89.895
vs LGVN: -1844.49
Longeveron (NAS:LGVN) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Longeveron Pretax Margin % Related Terms
Longeveron Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Longeveron's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LGVN vs MRKR, PLUR, VYNE: Pretax Margin % Comparison
For the Biotechnology subindustry, Longeveron's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longeveron Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Longeveron's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Longeveron's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longeveron (LGVN) has a Pretax Margin % of -1,189.95% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Longeveron and its competitors. According to the industry distribution chart, Longeveron ranks #785 out of 942 companies in the Biotechnology industry, placing it in the top 83.3%.
Is Longeveron's Pretax Margin % too high?
Longeveron's current Pretax Margin % is -1,189.95%. Based on the distribution chart, Longeveron ranks #785 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Longeveron has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Longeveron's Pretax Margin % compare to MRKR and PLUR?
According to the Biotechnology industry distribution chart, Longeveron ranks #785 out of 942 companies for Pretax Margin %. This places Longeveron in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Longeveron and its competitors. Longeveron's current Pretax Margin % is -1,189.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longeveron stock overvalued right now?
Based on GuruFocus' analysis, Longeveron (LGVN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.38, compared to a current price of $0.61 — trading 60.8% above its estimated fair value. The current Pretax Margin % is -1,189.95%. Longeveron's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Longeveron (LGVN), the current Pretax Margin % is -1,189.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Longeveron (LGVN) Overvalued in 2026?
Based on GuruFocus' analysis, Longeveron stock appears to be overvalued.
The current stock price of $0.61 is trading 60.8% above its estimated GF Value™ of $0.38.
GuruFocus considers Longeveron to be Significantly Overvalued.
Key valuation signals for LGVN:
Pretax Margin %: -1,189.95%
GF Value™: $0.38 vs. price of $0.61 (60.8% above fair value)
No single metric tells the full story. See the LGVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
45GF Score
Get the complete analysis for LGVN
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LGVN has been successfully added to your 
